{"id":3960,"date":"2018-03-05T17:06:00","date_gmt":"2018-03-05T22:06:00","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3960"},"modified":"2018-03-05T17:06:00","modified_gmt":"2018-03-05T22:06:00","slug":"secondaries-announced-3-5-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-3-5-18\/","title":{"rendered":"Secondaries Announced 3.5.18"},"content":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis.<\/strong><\/h4>\n

If having\u00a0real-time alerts for secondary offerings<\/strong><\/a>\u00a0would be an advantage to you,\u00a0inquire about a subscription today!<\/a><\/p>\n

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.<\/p>\n

 <\/p>\n

Company: Park Hotels & Resorts, Inc.
\nSymbol: PK
\nPrice: Last Trade $24.69
\nTrade Date: 3\/7
\nShares: 32.95 million
\nUnderwriter(s): Barclays, J.P. Morgan, UBS, Goldman Sachs, Morgan Stanley, Deutsche Bank, Credit Suisse, BofA Merrill Lynch
\nDescription: Park is a leading lodging REIT with a diverse portfolio of hotels and resorts with significant underlying real estate value. Park’s portfolio consists of 67 premium-branded hotels and resorts with over 35,000 rooms located in prime United States and international markets with high barriers to entry.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: SCYNEXIS
\nSymbol: SCYX
\nPrice: Last Trade $1.69
\nTrade Date: 3\/6
\nShares: 11.8 million ($20 million cash raise)
\nRe-Offer Range: Subscription Needed<\/a><\/strong>.
\nUnderwriter(s): Guggenheim Securities
\nDescription: SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs.
\nRating = Subscription Needed<\/a><\/strong>
\nNote: Warrants attached to the offering<\/p>\n

Company: Ares Management L.P.
\nSymbol: ARES
\nPrice: Last Trade $25.25
\nTrade Date: 3\/8
\nShares: 5 million
\nUnderwriter(s): Wells Fargo, Morgan Stanley, Credit Suisse, BofA Merrill Lynch, UBS, RBC
\nDescription: They are a publicly traded, leading global alternative asset manager with approximately $106.4 billion of assets under management as of December 31, 2017 and 18 offices in the United States, Europe, Asia and Australia.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: G1 Therapeutics
\nSymbol: GTHX
\nPrice: Last Trade $26.36
\nTrade Date: 3\/8
\nShares: 3 million
\nUnderwriter(s): J.P. Morgan, Cowen
\nCo-Manager(s): Needham & Co., Wedbush PacGrow, BTIG
\nDescription: They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Progress Software Corporation- Block
\nSymbol: PRGS
\nPrice: Last Trade $46.84
\nTrade Date: 3\/6
\nShares: 3.7 million
\nRe-Offer Range: Subscription Needed<\/a><\/strong>
\nUnderwriter(s): Morgan Stanley
\nDescription:Progress is a global software company.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: TransUnion – BLOCK
\nSymbol: TRU
\nPrice: Last Trade $57.98
\nTrade Date: 3\/6
\nShares: 19.9 million
\nRe-Offer Range: Subscription Needed<\/a><\/strong>
\nUnderwriter(s): J.P. Morgan, Morgan Stanley
\nDescription: TransUnion is a leading global risk and information solutions provider to businesses and consumers.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Centennial Resource Development Inc-BLOCK
\nSymbol: CDEV
\nPrice: Last Trade $20.06
\nTrade Date: 3\/6
\nShares: 22.4 million ($450m cash raise)
\nRe-Offer Range: Subscription Needed<\/a><\/strong>
\nUnderwriter(s): J.P. Morgan
\nDescription: They operate as an independent oil and natural gas company in the United States.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis. If having\u00a0real-time alerts for secondary offerings\u00a0would be an advantage to you,\u00a0inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[1087,1477,1479,1231,1478,325,501],"class_list":["post-3960","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings","tag-ares","tag-cdev","tag-gthx","tag-pk","tag-prgs","tag-scyx","tag-tru"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3960"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3960\/revisions"}],"predecessor-version":[{"id":3961,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3960\/revisions\/3961"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}